01—Abstract
Summary
Summary of the 10-Q filed May 19, 2026. Cited figures are marked; the original filing is the authoritative source.
Bryn Inc. (BRRN) filed its quarterly report for the period ending March 31, 2026.
The company continues to operate as a shell company with no current operations or revenue, primarily incurring administrative expenses. As of March 31, 2026, Bryn Inc. reported total assets of $2,178a and total liabilities of $36,440, resulting in a stockholders' deficit of $34,263. The company experienced a net loss of $30,937 for the quarter, a notable increase from the $16,410 loss in the same period last year, primarily driven by higher administrative expenses.
A significant development noted is the substantial increase in outstanding common shares from approximately 419.98 million at the end of 2025 to 450 million by March 31, 2026. This increase is largely attributed to the issuance of 30,015,577 common shares to Mr. Lazar to reduce related party debt, amounting to $93,285b.
Furthermore, subsequent to the quarter end, on April 24, 2026, MEDO Healthcare LLC acquired 10 million shares of Series A-1 Preferred Stock and plans to rename the company to MEDO Technologies, Inc., signaling a potential shift in business direction. The company's management acknowledges substantial doubt about its ability to continue as a going concern due to insufficient working capital and plans to seek additional financing and potentially explore acquisitions.
02—Key points
Key Highlights
- Bryn Inc. reported a net loss of $30,937 for the three months ended March 31, 2026, an increase from $16,410 in the prior year period.
- Total assets stood at $2,178 as of March 31, 2026, with liabilities totaling $36,440, leading to a stockholders' deficit of $34,263.
- The number of outstanding common shares increased to 450,000,000 as of March 31, 2026, up from approximately 419.98 million at year-end 2025.
- Approximately $93,285 in related party debt was settled through the issuance of 30,015,577 common shares to Mr. Lazar.
- Subsequent to the quarter, on April 24, 2026, MEDO Healthcare LLC acquired Series A-1 Preferred Stock and plans to rename the company to MEDO Technologies, Inc., indicating a potential strategic shift.
- The company acknowledges substantial doubt about its ability to continue as a going concern, citing insufficient working capital and the need for further financing.
- Management has identified material weaknesses in internal controls, including lack of segregation of duties, absence of an independent board/audit committee, and reliance on a financial consultant.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2026filed May 19, 2026Financial Statements
Q1 FY2026 against Q1 FY2025
| Line item | Q1 FY2026Q1 FY2025 | Change |
|---|---|---|
| Operating Expenses | $31K$16K | +88.5% |
| Operating Income | -$31K-$16K | −88.5% |
| Net Income | -$31K-$16K | −88.5% |
| Shares Outstanding (Basic) | 450.00M419.76M | +7.2% |
05—Questions
Frequently Asked Questions
What is Bryn Inc.'s current business and financial status?
Bryn Inc. currently has no operations or revenue. The company primarily incurs administrative expenses. As of March 31, 2026, it reported a net loss of $30,937 for the quarter and a total deficit of $34,263. The company acknowledges substantial doubt about its ability to continue as a going concern due to insufficient working capital and is actively seeking additional financing.
What significant changes occurred in the company's equity structure during the quarter?
During the quarter ended March 31, 2026, the number of outstanding common shares increased to 450,000,000 from approximately 419.98 million at the end of 2025. This increase was primarily due to the issuance of 30,015,577 common shares to Mr. Lazar, valued at $93,285, in settlement of related party debt.
What are the implications of the subsequent event regarding MEDO Healthcare LLC?
Subsequent to the quarter end, on April 24, 2026, MEDO Healthcare LLC purchased 10 million shares of Series A-1 Preferred Stock and plans to rename the company to MEDO Technologies, Inc. This suggests a potential change in business focus and ownership, with MEDO Healthcare intending to acquire and optimize pharmaceutical distributors using AI-based technology.
What are the key risks and control deficiencies highlighted in the report?
The company faces significant going concern risks due to a lack of working capital. Management has also identified material weaknesses in internal controls, including insufficient segregation of duties, the absence of an independent board of directors and audit committee, and a reliance on external financial consultants. These issues are planned to be addressed upon completion of a reverse merger or similar business acquisition.
06—Continue